CD24 Modulates Chemosensitivity of MCF-7 Breast Cancer Cells.
The role of cluster of differentiation (CD) 24 in breast cancer remains unclear; previously, we showed that CD24 suppresses malignant phenotypes by inactivating Hedgehog signaling through signal transducer and activator of transcription (STAT) 1 inhibition. In this study, we examined how CD24 affects chemosensitivity in breast cancer cells. The CD44+CD24+breast cancer cell line MCF-7 was transfected with CD24 with/without STAT1 siRNA, and chemosensitivity to 5-fluorouracil (5-FU) and cis-diamminedichloroplatinum (CDDP) was measured. CD24 inhibition reduced chemosensitivity to 5-FU, while STAT1 inhibition did not affect chemosensitivity to 5-FU in CD24 siRNA-transfected cells. Conversely, CD24 inhibition did not affect chemosensitivity to CDDP, while STAT1 inhibition reduced chemosensitivity to CDDP in CD24 siRNA-transfected cells. STAT1 inhibition, but not CD24 inhibition, reduced expression of the ATP-binding cassette (ABC) transporter genes, ABCB1 and ABCG2. In conclusion, CD24 inhibition may modulate chemosensitivity according to drug type, but ABC transporter expression appears not to contribute to this mechanism. This study contributes to determining the role of CD24 in breast cancer.
Department of Cancer Therapy and Research, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan ohnishi@surg1.med.kyushu-u.ac.jp.
Hideya
H
Onishi
Department of Cancer Therapy and Research, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Kumi
K
Suyama
Department of Cancer Therapy and Research, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Akio
A
Yamasaki
Department of Cancer Therapy and Research, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Yasuhiro
Y
Oyama
Department of Cancer Therapy and Research, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Akiko
A
Fujimura
Department of Cancer Therapy and Research, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Makoto
M
Kawamoto
Shukoukai Inc., Tokyo, Japan.
Akira
A
Imaizumi
D064286:ATP Binding Cassette Transporter 1 / Q000096:biosynthesis; D018435:ATP Binding Cassette Transporter, Subfamily B / Q000096:biosynthesis; D000070997:ATP Binding Cassette Transporter, Subfamily G, Member 2 / Q000096:biosynthesis; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism*; D051927:CD24 Antigen / Q000235:genetics / Q000378:metabolism*; D005260:Female; D005472:Fluorouracil / Q000494:pharmacology; D006801:Humans; D061986:MCF-7 Cells; D009363:Neoplasm Proteins / Q000096:biosynthesis; D034741:RNA, Small Interfering / Q000008:administration & dosage / Q000235:genetics; D050794:STAT1 Transcription Factor / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D014162:Transfection
C577836:ABCA1 protein, human; C513055:ABCB1 protein, human; C116614:ABCG2 protein, human; D064286:ATP Binding Cassette Transporter 1; D018435:ATP Binding Cassette Transporter, Subfamily B; D000070997:ATP Binding Cassette Transporter, Subfamily G, Member 2; D051927:CD24 Antigen; C497889:CD24 protein, human; D009363:Neoplasm Proteins; D034741:RNA, Small Interfering; D050794:STAT1 Transcription Factor; C494079:STAT1 protein, human; D005472:Fluorouracil
CD24; MCF-7 cells; breast cancer; cancer stem cell; chemosensitivity